BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 28654630)

  • 1. PROGNOSTIC VALUE OF SUBRETINAL HYPERREFLECTIVE MATERIAL IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB.
    Pokroy R; Mimouni M; Barayev E; Segev F; Geffen N; Nemet AY; Segal O
    Retina; 2018 Aug; 38(8):1485-1491. PubMed ID: 28654630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subretinal hyperreflective material morphology in neovascular age-related macular degeneration: A case control study.
    Alex D; Giridhar A; Gopalakrishnan M; Indurkhya S; Madan S
    Indian J Ophthalmol; 2021 Jul; 69(7):1862-1866. PubMed ID: 34146045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.
    Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CORRELATION BETWEEN OPTICAL COHERENCE TOMOGRAPHIC HYPERREFLECTIVE FOCI AND VISUAL OUTCOMES AFTER ANTI-VEGF TREATMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION AND POLYPOIDAL CHOROIDAL VASCULOPATHY.
    Lee H; Ji B; Chung H; Kim HC
    Retina; 2016 Mar; 36(3):465-75. PubMed ID: 26076214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials.
    Jaffe GJ; Ying GS; Toth CA; Daniel E; Grunwald JE; Martin DF; Maguire MG;
    Ophthalmology; 2019 Feb; 126(2):252-260. PubMed ID: 30189282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined fluorescein angiography and spectral-domain optical coherence tomography imaging of classic choroidal neovascularization secondary to age-related macular degeneration before and after intravitreal ranibizumab injections.
    Coscas F; Querques G; Forte R; Terrada C; Coscas G; Souied EH
    Retina; 2012 Jun; 32(6):1069-76. PubMed ID: 22466476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CORRELATION OF SUBRETINAL HYPERREFLECTIVE MATERIAL MORPHOLOGY AND VISUAL ACUITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
    Kumar JB; Stinnett S; Han JIL; Jaffe GJ
    Retina; 2020 May; 40(5):845-856. PubMed ID: 31305505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PROGNOSTIC VALUE OF HYPERREFLECTIVE FOCI IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB.
    Segal O; Barayev E; Nemet AY; Geffen N; Vainer I; Mimouni M
    Retina; 2016 Nov; 36(11):2175-2182. PubMed ID: 27078799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
    Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
    Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PREDICTING RESPONSE OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION TO BEVACIZUMAB BASED ON SPECTRALIS OPTICAL COHERENCE TOMOGRAPHY.
    Segal O; Barayev E; Nemet AY; Mimouni M
    Retina; 2016 Feb; 36(2):259-63. PubMed ID: 26200510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
    Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
    Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
    Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and Quantification of the Angiofibrotic Switch in Neovascular AMD.
    Roberts PK; Zotter S; Montuoro A; Pircher M; Baumann B; Ritter M; Hitzenberger CK; Schmidt-Erfurth U
    Invest Ophthalmol Vis Sci; 2019 Jan; 60(1):304-311. PubMed ID: 30657855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration.
    Emerson MV; Lauer AK; Flaxel CJ; Wilson DJ; Francis PJ; Stout JT; Emerson GG; Schlesinger TK; Nolte SK; Klein ML
    Retina; 2007; 27(4):439-44. PubMed ID: 17420695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Vascular Versus Avascular Subretinal Hyperreflective Material With Aflibercept Response in Age-related Macular Degeneration.
    Kawashima Y; Hata M; Oishi A; Ooto S; Yamashiro K; Tamura H; Miyata M; Uji A; Ueda-Arakawa N; Tsujikawa A
    Am J Ophthalmol; 2017 Sep; 181():61-70. PubMed ID: 28669776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid.
    Cuesta-Lasso M; Vieira-Barros A; Dolz-Marco R; Roig-Revert MJ; Badal J; Amselem L; Díaz-Llopis M; Gallego-Pinazo R
    Arch Soc Esp Oftalmol; 2017 Mar; 92(3):101-106. PubMed ID: 27912913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM
    Prog Retin Eye Res; 2016 Jan; 50():1-24. PubMed ID: 26307399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.
    Sharma S; Toth CA; Daniel E; Grunwald JE; Maguire MG; Ying GS; Huang J; Martin DF; Jaffe GJ;
    Ophthalmology; 2016 Apr; 123(4):865-75. PubMed ID: 26783095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.